Monitoring Anti-NS1 Antibodies in West Nile Virus-Infected and Vaccinated Horses

Table 1

Details of the horse serum samples used in this study.

WNV strain or vaccine	Sample group number	Infection mode	Nº  of serum samples	Nº  of animals	dpi/dpv	Source/origin	Confirmatory test
			Experimental
Israel ’98 (L1)	A1	Experimental	8	1	0-58	France	IgG,IgM,VNT
Austria ’08 (L2)	A1	Experimental	8	1	0-58	France	IgG,IgM,VNT
Equip	B1	Vaccine (experimental)	50	5	0-115	Spain
			Field
Unknown	A2	Natural	22	22		France	IgG, IgM
＇＇	A3	Natural	17	17		Italy	IgM
＇＇	A4	Natural	24	24		Morocco	IgM,IgG
＇＇	A5	Natural	52	52		Spain	IgM, VNT
Equip	B2	Vaccine	26	26		Spain
Proteq WNV	B3	Vaccine	30	30		Spain
Proteq WNV	B4	Vaccine	76	76		Spain
WNVVa	B5	Vaccine	13	13		Morocco
Recombite + WNVac	B6	Vaccine	19	19		Morocco
None	C	Field (no exposure to WNV)	96	96		Spain

a. Duvaxyne WNV (called now Equip WNV) commercially available by Zoetis. Inactivated WNV, strain VM-2 injectable. Administration route 2 doses IM/annual recalled.
b. Proteq WNV commercially available by Merial. Recombinant virus canary pox containing PrM-E WNV proteins. Administration route 2 doses IM/annual recalled.
c. WNV Vac commercially available by Biopharma. Inactivated WNV, strain Maroc 96-107 injectable. Administration route 2 doses IM/annual recalled.
d. Recombitek equine WNV. The same vaccine as Proteq WNV (b) but lyophilized presentation.